Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was ...

The financial markets responded immediately, with BioNTech shares declining as much as 5% in pre-market trading. This partnership has historically formed the cornerstone of BioNTech's commercial ...

Sources told CBS News, Reverend Jesse L. Jackson Sr. is on a form of life support. However, the family released a statement ...

WARNING: GRAPHIC CONTENT A grieving husband has claimed his wife died from complications of the Johnson & Johnson COVID-19 ...

Valneva's trajectory was significantly altered in August when the U.S. Food and Drug Administration (FDA) suspended the license for its Chikungunya vaccine IXCHIQ®, citing safety concerns. This ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Global biopharmaceutical sales were $16.3 billion, down 6%. Primary Care sales were down 16% to $7.6 billion. Eliquis sales ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Bidding war goes down to wire for company whose lead drug is potential alternative to vaccines for vulnerable patients ...